HEPA vs. FLGC, SNSE, IMNN, BGXX, AIM, HOTH, CRVO, WENA, RLMD, and CLDI
Should you be buying Hepion Pharmaceuticals stock or one of its competitors? The main competitors of Hepion Pharmaceuticals include Flora Growth (FLGC), Sensei Biotherapeutics (SNSE), Imunon (IMNN), Bright Green (BGXX), AIM ImmunoTech (AIM), Hoth Therapeutics (HOTH), CervoMed (CRVO), ANEW Medical (WENA), Relmada Therapeutics (RLMD), and Calidi Biotherapeutics (CLDI). These companies are all part of the "pharmaceutical products" industry.
Hepion Pharmaceuticals vs.
Flora Growth (NASDAQ:FLGC) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.
Flora Growth has a beta of 2.05, meaning that its share price is 105% more volatile than the S&P 500. Comparatively, Hepion Pharmaceuticals has a beta of 1.7, meaning that its share price is 70% more volatile than the S&P 500.
36.0% of Flora Growth shares are held by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are held by institutional investors. 13.0% of Flora Growth shares are held by company insiders. Comparatively, 2.0% of Hepion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Hepion Pharmaceuticals has a net margin of 0.00% compared to Flora Growth's net margin of -30.99%. Flora Growth's return on equity of -268.17% beat Hepion Pharmaceuticals' return on equity.
Hepion Pharmaceuticals received 6 more outperform votes than Flora Growth when rated by MarketBeat users. Likewise, 67.74% of users gave Hepion Pharmaceuticals an outperform vote while only 60.00% of users gave Flora Growth an outperform vote.
Hepion Pharmaceuticals has lower revenue, but higher earnings than Flora Growth.
In the previous week, Hepion Pharmaceuticals' average media sentiment score of 1.00 beat Flora Growth's score of 0.00 indicating that Hepion Pharmaceuticals is being referred to more favorably in the news media.
Flora Growth presently has a consensus target price of $5.00, indicating a potential upside of 433.62%. Given Flora Growth's stronger consensus rating and higher possible upside, equities analysts plainly believe Flora Growth is more favorable than Hepion Pharmaceuticals.
Summary
Flora Growth beats Hepion Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
Get Hepion Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for HEPA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hepion Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:HEPA) was last updated on 1/21/2025 by MarketBeat.com Staff
Free HEPA Stock Alerts